Patents Examined by Eliane Lazar-Wesley
-
Patent number: 6043211Abstract: DNA sequences encoding human platelet-derived growth factor receptors (hPDGF-R), and expression constructs comprising sequences which encode a receptor that can be secreted or incorporated into the membrane of a mammalian cell. Peptide fragments with functions equivalent to the wild-type receptor, conferring a PDGF-sensitive mitogenic response on cells lacking the receptor are provided. The constructs can be used for enhancing PDGF response of cells, determining the regions involved in transducing the signal in response to PDGF binding, providing mutated analogs and evaluating drugs for their physiologic activity. Soluble fragments comprising PDGF receptor sequences are also provided, including important intracellular kinase insert sequences which interact with intracellular proteins.Type: GrantFiled: June 5, 1995Date of Patent: March 28, 2000Assignee: The Regents of the University of CaliforniaInventors: Lewis Thomas Williams, Jaime A. Escobedo
-
Patent number: 6040187Abstract: The method for determining a suppressor component of human immune status comprises collecting peripheral blood, obtaining a suspension of mononuclear cells (MNCs), dividing said suspension into two equal portions, cultivating MNCs in the first portion without a suppressor activator, cultivating MNCs in the second portion with said suppressor activator (TBG), washing MNCs out of culture medium, blocking the proliferation, adding newly isolated MNCs from a normal donor, which MNCs have been stimulated with phytohemagglutinin, into each of MNC portions in equal proportions to obtain test cultures, cultivating said test cultures, further evaluating the proliferation in said test cultures and determining the suppression value on the basis of the ratios of proliferation levels in test cultures.Type: GrantFiled: January 21, 1997Date of Patent: March 21, 2000Assignees: Ivan Nikolaevich Golovistikov, Leonid Yazonovich KacharavaInventors: Ivan Nikolaevich Golovistikov, Leonid Yazonovich Kacharava, Khallar Abdumuslimovich Alikhanov
-
Patent number: 6033871Abstract: A genomic DNA encoding a human imidazoline receptor is described. cDNAs encoding the receptor and fragments thereof are also provided. An amino acid sequence predicted to be 120,000 MW for nearly the entire protein is identified, as well as a middle fragment believed to contain the imidazoline binding site of the receptor. The protein is highly unique in its sequence and may represent the first in a novel family of receptor proteins. Methods of cloning the cDNA and expressing the imidazoline receptor in a host cell are described. Methods of preparing antibodies against the transfected protein are also described. Also, a screening method for identifying additional subtypes of this receptor are identified. Also, screening methods for identifying drugs that interact with the imidazoline receptor are described.Type: GrantFiled: September 3, 1997Date of Patent: March 7, 2000Assignee: The University of Mississppi Medical CenterInventors: John E. Piletz, Tina R. Ivanov
-
Patent number: 6033903Abstract: The extracellular domain, or fragment thereof, of a gonadotropin glycoprotein hormone receptor is expressed and secreted in a soluble and functionally hormone-binding form. A recombinant baculovirus transfer vector is constructed to include a gene segment encoding the extracellular domain, or fragment thereof, of the glycoprotein hormone receptor joined in frame with a gene segment encoding a baculovirus signal peptide and operably linked to a baculovirus promoter. Recombinant baculovirus generated by transfection or co-transfection of insect cells are then used to infect insect host cells for the expression and secretion of soluble receptor.Type: GrantFiled: June 2, 1995Date of Patent: March 7, 2000Assignee: Applied Research Systems, Ars Holding N.V.Inventors: William P. Sisk, Shirley Vui Yen Cheng, David Rogers Buckler, Holly Lynn Prentice
-
Patent number: 6022704Abstract: DNA encoding human neuronal nicotinic acetylcholine receptor alpha and beta subunits, mammalian and amphibian cells containing said DNA, methods for producing alpha and beta subunits and recombinant (i.e., isolated or substantially pure) alpha subunits (specifically .alpha..sub.4 and .alpha..sub.7) and beta subunits (specifically .beta..sub.4) are provided. In addition, combinations of subunits (i.e., .alpha..sub.1, .alpha..sub.2, .alpha..sub.3, .alpha..sub.4, and/or .alpha..sub.7 subunits in combination with .beta..sub.4 subunits; or .beta..sub.2, .beta..sub.3 and/or .beta..sub.4 subunits in combination with .alpha..sub.4 and/or .alpha..sub.7 subunits) are provided.Type: GrantFiled: June 5, 1995Date of Patent: February 8, 2000Assignee: SIBIA Neurosciences, Inc.Inventors: Kathryn J. Elliott, Steven B. Ellis, Michael M. Harpold
-
Patent number: 6015690Abstract: A cDNA encoding a human imidazoline receptor is described. The amino acid sequence of the entire imidazoline receptor protein is identified, as well as a C-terminal fragment believed to contain the imidazoline binding site of the receptor. The protein is highly unique in its sequence and may represent the first in a novel family of receptor proteins. Methods of cloning the cDNA and pressing the imidazoline receptor in a host cell are described. Also, a screening method for identifying drugs that interact with the imidazoline receptor is described.Type: GrantFiled: May 20, 1996Date of Patent: January 18, 2000Assignee: The University of Mississippi Medical CenterInventors: John E. Piletz, Tina R. Ivanov
-
Patent number: 6013474Abstract: Calcium channel (alpha).sub.1 -subunit and (alpha).sub.2 -subunit-encoding DNA, and related compositions and methods, are provided.Type: GrantFiled: June 27, 1997Date of Patent: January 11, 2000Assignee: Sibia Neurosciences, Inc.Inventors: Steven Bradley Ellis, Mark E. Williams, Michael Miller Harpold, Arnold Schwartz, Robert Brenner
-
Patent number: 6008322Abstract: The present invention relates to polynucleotide and polypeptide molecules for stanniocalcin-2, a novel member of the stanniocalcin family. The polypeptides, and polynucleotides encoding them, modulate electrolyte homeostasis. The present invention also includes antibodies to the stanniocalcin-2 polypeptides.Type: GrantFiled: April 1, 1997Date of Patent: December 28, 1999Assignee: ZymoGenetics, Inc.Inventors: Rolf E. Kuestner, Darrell C. Conklin, Si Lok, Michele Buddle, William Downey
-
Patent number: 5989603Abstract: Shaped, unbaked dough products are provided that are coated with a glaze comprising an amount of water, oil and a hydrophilic colloid. The application of the glaze to the dough products, followed by baking, mimics the frying step which is traditionally used in the production process of certain dough products.Type: GrantFiled: January 10, 1997Date of Patent: November 23, 1999Assignee: The Pillsbury CompanyInventors: Dennis Lonergan, Michelle Larsen
-
Patent number: 5986065Abstract: The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF:VIIa complex, effectively preventing factor X binding to TF or that complex, and thereby reducing blood coagulation. Preferred antibodies of the invention specifically bind a conformational epitope predominant to native human TF, which epitope provides an unexpectedly strong antibody binding site.Type: GrantFiled: March 10, 1997Date of Patent: November 16, 1999Assignee: Sunol Molecular CorporationInventors: Hing C. Wong, Jin-An Jiao, Esperanza Liliana Nieves, Lawrence Luepschen
-
Patent number: 5985608Abstract: The invention relates to supervillin polypeptides, nucleic acid molecules encoding supervillin, and uses thereof. Supervillin is related to the actin-binding proteins villin and gelsolin.Type: GrantFiled: October 31, 1997Date of Patent: November 16, 1999Assignee: University of MassachusettsInventors: Elizabeth J. Luna, Kersi N. Pestonjamasp, Robert K. Pope, Julia D. Wulfkuhle
-
Patent number: 5981220Abstract: A human epidermal differentiation factor polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for treating and/or preventing skin diseases. Diagnostic assays for detecting mutations in a nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed.Type: GrantFiled: March 12, 1997Date of Patent: November 9, 1999Assignee: Human Genome Sciences, Inc.Inventors: Jian Ni, Ping Feng, Patrick J. Dillon, Reiner Gentz
-
Patent number: 5976831Abstract: Soluble and membrane-bound forms of human Fc.gamma.RIII are provided, together with nucleic acids capable of encoding the same. Soluble Fc.gamma.RIIIs are useful in ameliorating the serum platelet deficiency associated with immune thrombocytopenic purpura. Cells expressing membrane-bound Fc.gamma.RIII are useful components in assays for serum immune complexes.Type: GrantFiled: April 5, 1995Date of Patent: November 2, 1999Assignee: Applied Research Systems ARS Holding, N.V.Inventors: Gary A. Peltz, Kevin W. Moore
-
Patent number: 5977070Abstract: A pharmaceutical composition for the nasal delivery of compounds useful for treating osteoporosis, comprising an effective amount of a physiologically active truncated analog of PTH or PTHrp, or salt thereof, in which amino acid residues (22-31) form an amphipathic .alpha.-helix, said residues (22-31) selected from (SEQ ID NOS: 85, 86, 26, 27, 28, 29, and 30); an absorption enhancer selected from the group consisting of dimethyl-.beta.-cyclodextrin and the bile acid surfactants; and water is provided.Type: GrantFiled: August 29, 1995Date of Patent: November 2, 1999Inventors: Christin Teresa Piazza, Michael Lloyd Radomsky, John Leonard Krstenansky, John Joseph Nestor, Jr., Brian Henry Vickery
-
Patent number: 5977298Abstract: The present invention relates to compounds represented by formula (I): ##STR1## wherein Z represents Gly or Cys; X represents an (.alpha.-amino acid residue; Y represents a natural calcitonin moiety, a partial natural calcitonin peptide moiety, or a natural calcitonin-like peptide moiety; m represents an integer of 5-8, .alpha.-amino acid residues represented by X being the same or different; and n represents an integer of 0-3; provided that when m is 5, the sequence of 4 C-terminal residues of --(X).sub.m -- is different from the sequence of the third to sixth amino acids of natural calcitonin, and pharmaceutically acceptable salts thereof.Type: GrantFiled: September 22, 1997Date of Patent: November 2, 1999Assignee: Kvowa Hakko Kogyo Co., Ltd.Inventors: Kenji Shibata, Motoo Yamasaki, Masako Hamada, Tatsuya Tamaoki, Nobuo Kosaka, Soichiro Sato
-
Patent number: 5977318Abstract: The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.Type: GrantFiled: June 7, 1995Date of Patent: November 2, 1999Assignee: Bristol Myers Squibb CompanyInventors: Peter S. Linsley, Jeffrey A. Ledbetter, Nitin K. Damle, William Brady, Peter A. Kiener
-
Patent number: 5972718Abstract: A method of detecting heparin-induced antibodies to complete a diagnosis of heparin-induced thrombocytopenia HITP is disclosed. In one embodiment, this method comprises binding human platelet factor 4 to a linear, non-glycosaminoglycan polymer carrying negative charges distributed along the polymer chain, wherein the negative charge carried by the polymer is less than 10 .ANG. from the polymer chain. In another embodiment, the negative charge is a strong negative charge. A complex having one or more epitopes recognizable by antibodies generated in a HITP immune response is formed. One then contacts blood plasma or serum from a human patient suspected of having HITP with the complex and analyzes the complex to determine if the HITP-related antibodies are present. In another embodiment of the invention, a kit for diagnosing HITP is disclosed.Type: GrantFiled: February 21, 1997Date of Patent: October 26, 1999Assignees: The Blood Center Research Foundation, Genetics Testing InstituteInventors: Manouchehr Moghaddam, Gian Visentin, Richard H. Aster, Benjamin W. Boldt
-
Patent number: 5968510Abstract: The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.Type: GrantFiled: October 4, 1996Date of Patent: October 19, 1999Assignee: Bristol-Myers Squibb CompanyInventors: Peter S. Linsley, Jeffrey A. Ledbetter, Nitin K. Damle, William Brady, Peter A. Kiener
-
Patent number: 5965180Abstract: Shaped, unbaked dough products are provided that are coated with a glaze comprising an amount of water, a reducing sugar and a hydrophilic colloid. When baked, the dough products produce a finished product with increased horizontal dimensions over that which would be expected based on the raw dimensions of the unbaked dough product.Type: GrantFiled: January 10, 1997Date of Patent: October 12, 1999Assignee: The Pillsbury CompanyInventor: Dennis Lonergan
-
Patent number: 5958725Abstract: The invention provides a human DPl homolog (DPlh)) and polynucleotides which identify and encode DPlh. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of DPlh.Type: GrantFiled: May 29, 1997Date of Patent: September 28, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Karl J. Guegler, Purvi Shah, Joanne R. Petithory, Neil C. Corley